Antibody-Drug Conjugate– tag –
-
Redefining Colorectal Cancer Treatment: Breakthroughs in Bispecific Antibodies and ADCs
MDPI Switzerland Overview Bispecific antibodies (bsAbs) and antibody-drug conjugates (bsADCs) are ushering in a new era for colorectal cancer (CRC) treatment, offering solutions to challenges like tumor heterogeneity and drug resistance.... -
Samsung Biologics to Acquire PolyPeptide Group for $1.8B, Expanding CDMO Capabilities into Peptide Therapeutics with $2.2B Capital Raise
Endpoints News South Korea Overview Samsung Biologics announced a capital raise of nearly $2.2 billion to fund its long-term growth strategy, including the acquisition of PolyPeptide Group for $1.8 billion. This acquisition will signific... -
CDMO Curia Massively Expands Sterile Fill-Finish Capacity in UK, US for Biologics and ADCs
Packaging Digest UK, USA Overview CDMO Curia has significantly expanded its sterile fill-finish manufacturing facilities in Glasgow, UK, and Albuquerque, US, to meet surging demand for biologics and highly potent antibody-drug conjugates... -
WuXi XDC Reports $550.4M H1 Revenue (37% YoY Growth) and Reaffirms $1.2B Investment in ADC Manufacturing Capacity by 2030
Fierce Biotech China Overview WuXi XDC, the ADC-focused subsidiary of WuXi Bio, reported a significant 37% year-over-year revenue increase to RMB 3.7 billion (approximately $550.4 million) in the first half of 2026. The company also reaf... -
A*STAR Successfully Identifies Bispecific Antibody Stability Risks: Enhancing Manufacturability and Robustness of Next-Gen Biologics
A*STAR Singapore Overview Researchers at A*STAR's Bioprocessing Technology Institute (BTI) in Singapore have successfully identified 'labile regions' within bispecific antibodies (BsAbs) that compromise their manufacturing and stability.... -
Antibody-Drug Conjugate (ADC) Development Guide: Precise Design of Monoclonal Antibodies, Linkers, and Payloads is Key
Allucent USA Overview Antibody-Drug Conjugates (ADCs) combine three engineered components—a tumor-targeting monoclonal antibody, a chemical linker, and an active payload—to deliver potent cancer therapy. Upon binding to the target, ADCs ... -
PitchBook Analysis: Rebounding Biotech Funding Expected to Drive CDMO Growth in 2026, Focus on Complex Modalities
BioSpace USA Overview This article provides an overview of a PitchBook analysis report. According to PitchBook, biotech venture capital funding in the first half of 2026 surpassed $10 billion, driven significantly by Isomorphic Labs' $2.... -
DCAT Report: 2026 CDMO Market Sees Major M&A and Capital Investments, with Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion
DCAT Value Chain Insights USA Overview According to a DCAT Value Chain Insights report, the 2026 CDMO market is witnessing a surge in peptide-based drug development, accompanied by significant M&A and capital investments. Samsung Bio... -
Serina Therapeutics Highlights POZ Platform’s Potential to Enhance Efficacy and Safety of Small Molecule, RNA, and ADC Therapies
BioSpace USA Overview Serina Therapeutics announced its Q2 2026 financial and business updates, emphasizing the advancement of its wholly-owned pipeline for neurological and other indications, powered by its proprietary POZ Platform™. Th... -
Daiichi Sankyo Leverages AI-Driven Biomarker Discovery with Tempus to Strengthen ADC Clinical Strategy
BioPharm International Japan Overview Daiichi Sankyo has announced a new partnership with AI-driven precision medicine company Tempus to enhance its antibody-drug conjugate (ADC) clinical strategy. This collaboration aims to improve pati...
